Open-Label, Multicenter, Phase 1 Study To Assess The Safety Of P BCMA-101 In Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed By A Phase 2 Assessment Of Response And Safety (PRIME) Read more
A Multicenter, Open-Label Study With A Randomized Control Arm Of The Efficacy, Safety, And Pharmacokinetics Of Intravenously Infused Berubicin In Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure Of Standard First Line Therapy Read more
Prospective Observational Multiple Myeloma Impact Study Prospective Multicenter Study To Measure The Impact Of Mmprofiler On Treatment Intention In Active Multiple Myeloma Patients Read more
A Phase 1/2 Study Of Selinexor In Combination With Standard Of Care (Soc) Therapy For Actively Diagnosed Or Recurrent Glioblastoma Read more
A Phase 1b/2 Study Of Selinexor (KPT-330) In Combination With Backbone Treatments For Relapsed/Refractory Multiple Myeloma Read more
Myeloma-Developing Regimens Using Genomics (Mydrug) (Genomics Guided Multi-Arm Trial Of Targeted Agents Alone Or In Combination With A Backbone Regimen) Read more
A Phase I/II Assessment Of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) And Anti-TGIT (BMS-986207) Read more
A Phase 1/2 Open-Label Study To Investigate The Safety And Tolerability, Efficacy, Pharmacokinetics, And Immunogenicity Of TAK-573 As A Single Agent In Patients With Refractory Multiple Myeloma Read more
A Phase I In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AMG 176 In Subjects With Relapsed Or Refractory Multiple Myeloma Read more
